-
-
-
-
-
-
-
UBS Starts Viridian Therapeutic (VRDN) at Buy
-
-
-
-
-
-
-
Goldman on Viridian (VRDN): 'believes the market can potentially grow ~2-3x at peak due to veli's and '003's potential to expand use in chronic TED'
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Viridian Therapeutic (VRDN)
-
-
-
-
-
-
-
Viridian Therapeutics (VRDN) Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on Viridian Therapeutic (VRDN)
-
-
-
-
-
-
-
Viridian Therapeutic (VRDN) PT Raised to $41 at Stifel
-
-
-
-
-
-
-
Viridian Therapeutic (VRDN) PT Raised to $38 at Needham
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

